HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fairfield, K. Articles by Stampfer, M. Search for Related Content PubMed PubMed Citation Articles by Fairfield, K. Articles by Stampfer, M. Agricola Articles by Fairfield, K. Articles by Stampfer, M.

Vitamin and mineral supplements for cancer prevention: issues and evidence^1,2,3,4

¹ From the Department of Medicine, Maine Medical Center, Portland, ME (KF), and the Department of Epidemiology, Harvard School of Public Health, Boston, MA, and the Channing Laboratory, Brigham and Women's Hospital, Boston, MA (MS)

ABSTRACT

Trials of nutritional supplements for cancer prevention must overcome a variety of challenges not shared in the usual paradigm of pharmaceutical agents for prevention of cardiovascular disease. Unlike for cardiovascular disease, for cancer we typically do not have well-established causal risk factors as targets for intervention. Also, for most likely cancer interventions, the expected time to achieve an effect is much longer, more variable, and far less well understood than for cardiovascular disease, and the progression of pathophysiology is much harder—or impossible—to follow, in contrast with imaging for progression of atherosclerosis in cardiovascular disease. Also, cancers at various sites have a wide range of etiologies. The optimal age for intervention, best dose, and duration needed to test nutritional agents for cancer prevention are largely unknown, making null findings hard to interpret. Unlike with drugs, baseline nutritional status can be critical. Moreover, because the nutritional agents are often readily available, adherence in control groups in trials can be impaired. Several gene-nutrient and nutrient-nutrient interactions have been identified that could affect trial results. Some studies suggest that particular nutrients may be effective only in subgroups defined by genotypes or by nutritional status of another nutrient. All these challenges must be considered in planning informative trials. Long-term prospective cohort studies, especially with repeated measures and high follow-up, can provide useful data for planning trials as well as the basis for rational recommendations while awaiting trial results or in settings where trials may be infeasible.

Key Words: Vitamins • mineral supplements • cancer prevention • clinical trials • epidemiology

This article has been cited by other articles:

				B. N Ames, J. C McCann, M. J Stampfer, and W. C Willett Evidence-based decision making on micronutrients and chronic disease: long-term randomized controlled trials are not enough Am. J. Clinical Nutrition, August 1, 2007; 86(2): 522 - 523. [Full Text] [PDF]